Anatomical Therapeutic Chemical • L04AX06 • pomalidomide

L Antineoplastic and immunomodulating agents

L01 Antineoplastic agents

L02 Endocrine therapy

L03 Immunostimulants

L04 Immunosuppressants

L04A Immunosuppressants

L04AA Selective immunosuppressants

L04AB Tumor necrosis factor alpha (tnf-alpha) inhibitors

L04AC Interleukin inhibitors

L04AD Calcineurin inhibitors

L04AE Sphingosine-1-phosphate (S1P) receptor modulators

L04AF Janus-associated kinase (JAK) inhibitors

L04AG Monoclonal antibodies

L04AH Mammalian target of rapamycin (mTOR) kinase inhibitors

L04AJ Complement inhibitors

L04AK Dihydroorotate dehydrogenase (DHODH) inhibitors

L04AL Neonatal fragment crystallizable receptor (fcrn) inhibitors

L04AX Other immunosuppressants

L04AX01 azathioprine Indicated for: immunosuppression

L04AX02 thalidomide Indicated for: cancer

L04AX03 methotrexate Indicated for: cancer; autoimmune inflammatory diseases

L04AX04 lenalidomide Indicated for: multiple myeloma

L04AX05 pirfenidone Indicated for: idiopathic pulmonary fibrosis

L04AX06 pomalidomide Indicated for: hematologic malignancies

L04AX07 dimethyl fumarate Indicated for: multiple sclerosis

L04AX08 darvadstrocel Indicated for: complex perianal fistulas in Crohn's disease

L04AX09 diroximel fumarate Indicated for: multiple sclerosis